| Autor: |
Stalker, Margaret, Grady, Connor B., Watts, Alex, Hwang, Wei-Ting, Chandrasekhara, Krishna, Sun, Fangdi, Liu, Geoffrey, Patel, Devalben, Nieva, Jorge, Herrmann, Amanda, Marrone, Kristen, Lam, Vincent K., Velcheti, Vamsidhar, Liu, Stephen V., Bravo Montenegro, Gabriela Liliana, Tompkins, William, Patil, Tejas, Weiss, Jared, Miller, Kelsey Leigh, Schwartzman, William, Dowell, Jonathan E., Shaverdashvili, Khvaramze, Villaruz, Liza, Cass, Amanda, Iams, Wade, Aisner, Dara, Aggarwal, Charu, Camidge, D. Ross, Sun, Lova, Marmarelis, Melina E. |
| Zdroj: |
JTO Clinical and Research Reports; January 2025, Vol. 6 Issue: 1 |
| Abstrakt: |
Osimertinib is now a standard first-line (1L) therapy for EGFR-mutated (EGFRm) advanced NSCLC. We aimed to characterize patterns of therapy and longitudinal risk of brain and liver metastasis in a cohort of EGFRm NSCLC. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
